Delisting risk
Invivyd (IVVD)
Develops monoclonal antibodies for serious viral diseases, beginning with COVID-19 prevention.
$0.8596
Pre-market+0.05 (+6.58%)
At close$0.8065(−8.34%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
in 63 days
EPS estimate
−$0.11
Revenue estimate
$15.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.15−$0.14−$0.12−$0.06$0.02−$0.13−$0.14Pending
Estimate−$0.25−$0.04−$0.04−$0.05−$0.06−$0.08−$0.11−$0.11
Surprise+40.0%−250.0%−200.0%−20.0%+133.3%−62.5%−31.2%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$13.8M$11.3M$11.8M$13.1M$17.2M$13.7M$14.3MPending
Estimate$34.5M$17.5M$29.0M$15.5M$17.2M$18.0M$14.4M$15.0M
Surprise−59.9%−35.4%−59.4%−15.4%0.0%−23.8%−0.8%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.11 | — | — |
| Aug 2026 | −$0.11 | −$0.14 | −31.2% |
| May 2026 | −$0.08 | −$0.13 | −62.5% |
| Mar 2026 | −$0.06 | $0.02 | +133.3% |
| Nov 2025 | −$0.05 | −$0.06 | −20.0% |
The latest year is open to everyone — the 21 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Sep 2021 | |||
| Aug 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.11 | — | — | $15.0M | — | — | — |
| Aug 13, 2026 | −$0.11 | −$0.14 | −31.2% | $14.4M | $14.3M | −0.8% | +5.1% |
| May 14, 2026 | −$0.08 | −$0.13 | −62.5% | $18.0M | $13.7M | −23.8% | +4.3% |
| Mar 5, 2026 | −$0.06 | $0.02 | +133.3% | $17.2M | $17.2M | 0.0% | +3.5% |
| Nov 6, 2025 | −$0.05 | −$0.06 | −20.0% | $15.5M | $13.1M | −15.4% | +3.3% |
The latest year is open to everyone — the 21 quarters behind it read with an account. Sign in | |||||||
| Aug 14, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 20, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 28, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 23, 2023 | |||||||
| Nov 10, 2022 | |||||||
| Aug 15, 2022 | |||||||
| May 13, 2022 | |||||||
| Mar 30, 2022 | |||||||
| Nov 15, 2021 | |||||||
| Sep 20, 2021 | |||||||
| Aug 6, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||